Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.87
OPK's Cash to Debt is ranked lower than
68% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. OPK: 2.87 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 24.15 Max: No Debt
Current: 2.87
Equity to Asset 0.72
OPK's Equity to Asset is ranked higher than
54% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OPK: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.72
-0.41
0.96
F-Score: 4
Z-Score: 3.84
M-Score: 4.39
WACC vs ROIC
14.78%
-4.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.18
OPK's Operating margin (%) is ranked higher than
66% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. OPK: -9.18 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44  Med: -82.88 Max: -20.03
Current: -9.18
-31624.44
-20.03
Net-margin (%) 9.98
OPK's Net-margin (%) is ranked higher than
80% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. OPK: 9.98 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9  Med: -118.52 Max: -4.59
Current: 9.98
-31688.9
-4.59
ROE (%) 4.94
OPK's ROE (%) is ranked higher than
81% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. OPK: 4.94 )
Ranked among companies with meaningful ROE (%) only.
OPK' s ROE (%) Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: -2.13
Current: 4.94
-3196.93
-2.13
ROA (%) 3.22
OPK's ROA (%) is ranked higher than
82% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. OPK: 3.22 )
Ranked among companies with meaningful ROA (%) only.
OPK' s ROA (%) Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: -0.83
Current: 3.22
-1352.71
-0.83
ROC (Joel Greenblatt) (%) -48.67
OPK's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. OPK: -48.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93  Med: -367.75 Max: -88.52
Current: -48.67
-130662.93
-88.52
Revenue Growth (3Y)(%) 85.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
93% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. OPK: 85.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.60 Max: 174.6
Current: 85.1
0
174.6
EBITDA Growth (3Y)(%) 27.20
OPK's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. OPK: 27.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.1  Med: 4.80 Max: 160.3
Current: 27.2
-74.1
160.3
EPS Growth (3Y)(%) -17.40
OPK's EPS Growth (3Y)(%) is ranked lower than
65% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. OPK: -17.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: -1.60 Max: 149.7
Current: -17.4
-66.2
149.7
» OPK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SGEN, OTCPK:SBMFF, NAS:DYAX, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JUNO, NAS:TECH, NAS:ALKS, OTCPK:BTGGF, NAS:ACAD, NAS:ICPT, OTCPK:LBTSF, NYSE:XON, NAS:CBPO, NAS:IONS, OTCPK:SOLTF, NAS:KITE, NAS:LGND, NAS:JAZZ » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.

Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.

Top Ranked Articles about OPKO Health Inc

Insider Buys of More Than $100,000: Opko Health Chairman purchases 16,000 shares in company
Opko Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160. Read more...
Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair These are the largest CEO buys during the past week, according to GuruFocus' Insider Data
These are the largest CEO buys during the past week, according to GuruFocus' Insider Data. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB A look at recent insider buys from CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals GuruFocus Insider Data identifies CEOs' largest buys in the past week.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY A roundup of recent insider buys
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 67.57
OPK's P/E(ttm) is ranked lower than
73% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. OPK: 67.57 )
Ranked among companies with meaningful P/E(ttm) only.
OPK' s P/E(ttm) Range Over the Past 10 Years
Min: 63.29  Med: 71.40 Max: 78.88
Current: 67.57
63.29
78.88
Forward P/E 384.62
OPK's Forward P/E is ranked lower than
97% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. OPK: 384.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 67.57
OPK's PE(NRI) is ranked lower than
74% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. OPK: 67.57 )
Ranked among companies with meaningful PE(NRI) only.
OPK' s PE(NRI) Range Over the Past 10 Years
Min: 63.29  Med: 71.40 Max: 78.88
Current: 67.57
63.29
78.88
P/B 2.58
OPK's P/B is ranked higher than
60% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. OPK: 2.58 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.17  Med: 8.86 Max: 800
Current: 2.58
2.17
800
P/S 6.44
OPK's P/S is ranked higher than
64% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. OPK: 6.44 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 6.16  Med: 34.05 Max: 158.13
Current: 6.44
6.16
158.13
EV-to-EBITDA 452.51
OPK's EV-to-EBITDA is ranked lower than
99% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. OPK: 452.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -35.95 Max: 539.9
Current: 452.51
-146.6
539.9
PEG 1.64
OPK's PEG is ranked higher than
59% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. OPK: 1.64 )
Ranked among companies with meaningful PEG only.
OPK' s PEG Range Over the Past 10 Years
Min: 0  Med: 83.73 Max: 10097.6
Current: 1.64
0
10097.6
Current Ratio 1.70
OPK's Current Ratio is ranked lower than
79% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OPK: 1.70 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.80 Max: 415
Current: 1.7
0.88
415
Quick Ratio 1.55
OPK's Quick Ratio is ranked lower than
77% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. OPK: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.11 Max: 415
Current: 1.55
0.48
415
Days Inventory 31.32
OPK's Days Inventory is ranked higher than
85% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. OPK: 31.32 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 43.67  Med: 233.05 Max: 500.07
Current: 31.32
43.67
500.07
Days Sales Outstanding 99.16
OPK's Days Sales Outstanding is ranked lower than
73% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. OPK: 99.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 143.91 Max: 727.85
Current: 99.16
38.86
727.85
Days Payable 71.97
OPK's Days Payable is ranked higher than
57% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. OPK: 71.97 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 66.48  Med: 112.55 Max: 1499.3
Current: 71.97
66.48
1499.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.75
OPK's Price/Projected FCF is ranked lower than
53% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. OPK: 3.75 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.04  Med: 11.72 Max: 78.89
Current: 3.75
3.04
78.89
Price/Median PS Value 0.19
OPK's Price/Median PS Value is ranked higher than
93% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. OPK: 0.19 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.30 Max: 30
Current: 0.19
0.21
30
Earnings Yield (Greenblatt) (%) -1.00
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. OPK: -1.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.03  Med: 0.00 Max: 0
Current: -1
-7.03
0

More Statistics

Revenue (TTM) (Mil) $752.7
EPS (TTM) $ 0.14
Beta1.78
Short Percentage of Float23.34%
52-Week Range $7.12 - 17.51
Shares Outstanding (Mil)547.44

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,207 1,379 1,971
EPS ($) 0.03 0.29 0.64
EPS w/o NRI ($) 0.03 0.29 0.64
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Insider Buys of More Than $100,000: Opko Health Jun 16 2016 
Weekly CEO Buys Highlights Mar 14 2016 
Weekly CEO Buys Highlights Jan 26 2016 
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016 
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016 
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko Health, Dec 28 2015 
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB Nov 02 2015 
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals Oct 16 2015 
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY Sep 12 2015 
Weekly CEO Buys Highlight: Shutterstock, Endurance Specialty Holdings, Opko, Air Products, KapStone Aug 31 2015 

More From Other Websites
Opko Health Inc (OPK) CEO & Chairman, 10% Owner Phillip Frost Bought $169,560 of Stocks Jun 23 2016
Opko Health Inc (OPK) Phillip Frost Bought $a69,56a of Stocks Jun 23 2016
Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session Jun 22 2016
Opko Health shares climb after FDA approves hormone treatment Jun 21 2016
Here's Why Opko Health (OPK) Stock Is Gaining Today Jun 21 2016
Opko's mangement and pipeline makes it a solid buy (OPK) Jun 21 2016
Opko (OPK) Stock Gains as FDA Approves Rayaldee Jun 21 2016
Company News for June 21, 2016 Jun 21 2016
Why Traders Are Buzzing about Lennar Corporation, Opko Health and Three Other Stocks on Tuesday Jun 21 2016
Morning Movers: BAC, MRO, NKE, OPK Jun 21 2016
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 21 2016
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated... Jun 21 2016
Trending Now: OPK Jun 20 2016
[$$] Despite Big Drop, Opko Health Stock Looks Pricey Jun 17 2016
Insider Buys of More Than $aaa,aaa: Opko Health Jun 16 2016
Opko Health Is Jumping to the Nasdaq Jun 15 2016
OPKO Health to Host Analyst & Investor Day in New York City on June 15 Jun 14 2016
OPKO Health to Host Analyst & Investor Day in New York City on June 15 Jun 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)